Cowen & Co. Sticks to Their Hold Rating for Akcea Therapeutics (AKCA)

By Carrie Williams

Cowen & Co. analyst Ritu Baral maintained a Hold rating on Akcea Therapeutics (AKCAResearch Report) today. The company’s shares closed last Monday at $20.04.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.0% and a 46.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

Akcea Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.50.

See today’s analyst top recommended stocks >>

Based on Akcea Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.32 million. In comparison, last year the company had a GAAP net loss of $63.59 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.